9
Views
1
CrossRef citations to date
0
Altmetric
Research Article

Eptifibatide does not influence lymphocyte activation and CRP levels in patients with undergoing coronary angioplasty

, , , , , & show all
Pages 107-109 | Published online: 10 Jul 2009

References

  • Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 14: 340: 115–26.
  • Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 17: 104: 365–72.
  • Lincoff AM, Califf RM, Topol EJ. Platelet glycoprotein lib/Ilia blockade in coronary artery disease. J Am Coll Cardiol 2000; 35: 1103–15.
  • George J, Ben-Shmuel S, Roth A et al. L-Arginine attenuates lymphocyte activation and anti-oxidized LDL antibody levels in patients undergoing angioplasty. Atherosclerosis 2004; 174: 323–7.
  • Lincoff AM, Kereiakes DJ, Marcelli MA et al. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 2001; 104: 163–7.
  • Topol EJ, Moliterno DJ, Herrmann HC et al. Comparison of two platelet glycoprotein IIB/IIIA inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344: 1937–9.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.